Fortress Biotech's earnings report is expected to have a neutral short-term impact on its stock price. While past earnings have resulted in price changes, the current estimate of $-0.20 EPS and the stock's 44.89% decline over the last 52 weeks make it difficult to predict a clear direction. The stock's performance will likely depend on whether the company beats or misses the estimate and provides positive or negative guidance for the next quarter.